Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Trial Profile

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Azacitidine (Primary) ; Belinostat (Primary) ; Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Rituximab (Primary) ; Filgrastim; Glutamine; Pyridoxine; Pyridoxine
  • Indications Diffuse large B cell lymphoma; Lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 03 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 11 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top